[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623620":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":97,"collaborators":10,"id":99,"slug":10,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":16,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":10,"enrollmentInfo":107,"targetDuration":110,"studyType":111,"phases":10,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Fundación EPIC","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Coronary Artery Disease (CAD)",null,[12],"Device: LONG NAGOMI",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DEVICE","LONG NAGOMI","Patients in whom treatment with long nagomi has been attempted",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"TAMARA GARCIA CAMARERO, MD, PhD","CONTACT","0034615420460","tgcamarero@gmail.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"FUNDACION EPIC","00987876135","iepic@fundacionepic.org",[30,43,52,61,70,79,88],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Hospital Universitario de Cabueñes","RECRUITING","Cabueñes","33394","Spain","ES",{"type":38,"coordinates":39},"Point",[40,41],-5.60569,43.52347,{"lat":41,"lon":40},{"facility":44,"status":32,"city":45,"state":10,"zip":46,"country":35,"countryCode":36,"cosmosGeoPoint":47,"geoPoint":51,"contacts":10},"Hospital General Universitario de Elche","Elche","03203",{"type":38,"coordinates":48},[49,50],-0.70107,38.26218,{"lat":50,"lon":49},{"facility":53,"status":32,"city":54,"state":10,"zip":55,"country":35,"countryCode":36,"cosmosGeoPoint":56,"geoPoint":60,"contacts":10},"Hospital Universitario Juan Ramón Jiménez","Huelva","21005",{"type":38,"coordinates":57},[58,59],-6.94004,37.26638,{"lat":59,"lon":58},{"facility":62,"status":32,"city":63,"state":10,"zip":64,"country":35,"countryCode":36,"cosmosGeoPoint":65,"geoPoint":69,"contacts":10},"Hospital Universitario de Leon","León","24008",{"type":38,"coordinates":66},[67,68],-5.57032,42.60003,{"lat":68,"lon":67},{"facility":71,"status":32,"city":72,"state":10,"zip":73,"country":35,"countryCode":36,"cosmosGeoPoint":74,"geoPoint":78,"contacts":10},"Hospital Universitario Regional de Málaga","Málaga","29010",{"type":38,"coordinates":75},[76,77],-4.42034,36.72016,{"lat":77,"lon":76},{"facility":80,"status":32,"city":81,"state":10,"zip":82,"country":35,"countryCode":36,"cosmosGeoPoint":83,"geoPoint":87,"contacts":10},"Hospital Universitario de Navarra","Pamplona","31008",{"type":38,"coordinates":84},[85,86],-1.64323,42.81687,{"lat":86,"lon":85},{"facility":89,"status":32,"city":90,"state":10,"zip":91,"country":35,"countryCode":36,"cosmosGeoPoint":92,"geoPoint":96,"contacts":10},"Hospital Universitario Marqués de Valdecilla","Santander","39008",{"type":38,"coordinates":93},[94,95],-3.80493,43.46589,{"lat":95,"lon":94},{"type":98,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100623620",false,"NCT07399002","LONG NAGOMI™ PMCF STUDY","Long Coronary Lesions: Safety and Performance of the Ultimaster Nagomi™ Stent in This Setting With a One-to-one Approach -One Lesion, One Stent- LONG NAGOMI™ PMCF STUDY","Inclusion Criteria:\n\n* Patients who meet ALL inclusion criteria will be included:\n* Patients aged ≥ 18 years AND;\n* Patients who according to standard practice of the hospital are amenable to PCI as indicated and considered adequate according to the European clinical practice guidelines on coronary revascularization AND;\n* Patients with at least one lesion fulfilling the \"long lesion criteria\" suitable for a single stent approach AND;\n* Patients who have been informed of the characteristics of the study and have provided written informed consent AND;\n* Intention to treat all lesions with the Ultimaster Nagomi™ stent\n\nExclusion Criteria:\n\n* Patients must not meet any of the following exclusion criteria:\n* Patients who expressly decline to participate in the study.\n* Pregnant or breastfeeding women.\n* Patients with acute coronary syndrome (ACS) under conditions of cardiogenic shock (Killip class 4).\n* Patients with contraindications or hypersensitivity to sirolimus.\n* Patients with a life expectancy of less than 2 years.\n* Patients in whom any surgery requiring general anesthesia is planned, comorbidity or indication likely necessitating the discontinuation of dual anti-platelet therapy before the recommended duration of dual anti-platelet therapy per the ESC or national guidelines.\n* Patients included in other clinical trials that did not reach the primary objective.","ALL","18 Years",{"count":108,"type":109},1039,"ESTIMATED","12 Months","OBSERVATIONAL","The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ \\_stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.",[114,115],"Coronary Artery Disease","Ischemic Heart Disease",[117,118],"MDR (Medical Device Regulations)","PMCF (Post-Market Clinical Follow-up)","2026-06-19",{"date":121,"type":122},"2026-06-23","ACTUAL",{"date":124,"type":122},"2026-02-27",{"date":126,"type":109},"2029-01-01",{"name":5,"class":6},7]